Analysts Boost Centessa Pharmaceuticals plc (CNTA) Price Targets as Sleep Disorder Drug Shows Breakthrough Results

Centessa Pharmaceuticals plc (NASDAQ:CNTA) is one of the best 52-week high stocks to buy right now. On December 1, B. Riley boosted its price target on Centessa Pharmaceuticals plc (NASDAQ:CNTA) to $42 from $33 and reiterated its Buy rating after impressive Phase 2 data for ORX750.

Analysts Boost Centessa Pharmaceuticals plc (CNTA) Price Targets as Sleep Disorder Drug Shows Breakthrough Results

The CRYSTAL-1 study showed strong wake-promoting effects at much lower doses than competing drugs, with meaningful benefits in narcolepsy type 2 and idiopathic hypersomnia: including an 87% drop in cataplexy episodes, and a clean safety profile. Analysts pointed to Centessa’s potential lead over other developers, rising investor support, and a growing market for orexin-based therapies, especially as the Alkermes-Avadel merger highlights momentum in the space ahead of expected launches starting in 2026.

Previously on November 18, analysts at Guggenheim lifted their price target of the stock to $43 from $28 while reiterating a Buy rating. The price target hike follows the company’s topline results from its ORX750 CRYSTAL-1 Phase 2a study. According to Guggenheim, Centessa remains well-positioned to advance ORX750 in pivotal trials following an equity financing that raised $619 million in pro forma cash. Development of the candidate drug could expand its addressable market by targeting neurodegenerative and neuropsychiatric disorders.

Centessa Pharmaceuticals plc (NASDAQ:CNTA) is a pharmaceutical company that discovers and develops transformational medicines for patients with high unmet needs. Its key programs include a hemophilia program, an orexin agonist program for sleep-wake disorders like narcolepsy, and an immune-oncology program.

While we acknowledge the potential of CNTA to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than CNTA and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: Top 10 Materials Stocks to Buy According to Analysts and 10 Best Organic Food and Farming Stocks to Buy Now.

Disclosure: None. This article is originally published at Insider Monkey.